Quantcast
Last updated on April 23, 2014 at 16:13 EDT

Latest Sophiris Bio Inc. Stories

2013-09-05 16:26:14

SAN DIEGO AND VANCOUVER, Sept. 5, 2013 /PRNewswire/ - Sophiris Bio Inc. (NASDAQ: SPHS, TSX: SHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing a clinical stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced that Randall E. Woods, President and Chief Executive Officer, will present a corporate overview at the Stifel Healthcare Conference 2013 at the Four Seasons Hotel in Boston,...

2013-08-23 12:23:52

SAN DIEGO and VANCOUVER, Aug. 23, 2013 /PRNewswire/ - Sophiris Bio Inc. (NASDAQ: SPHS, TSX: SHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced that it has closed its previously announced initial U.S. public offering (the "Offering"). The Company issued 13,000,000 common shares at a price of US$5.00 per share for aggregate gross...

2013-08-16 12:24:02

SAN DIEGO and VANCOUVER, Aug. 16, 2013 /PRNewswire/ - Sophiris Bio Inc. (Sophiris, TSX: SHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced that it has entered into an underwriting agreement with Citigroup and Leerink Swann, as joint book-running managers, with respect to an offering (the "Offering") of 13,000,000 common shares of...

2013-08-12 16:26:50

Share Consolidation in Anticipation of Listing on the NASDAQ Stock Market SAN DIEGO AND VANCOUVER, Aug. 12, 2013 /PRNewswire/ - Sophiris Bio Inc. (TSX: SHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced a 52-for-1 consolidation of its common shares traded on the Toronto Stock Exchange, effective August 9, 2013 (the "Effective...

2013-08-05 20:21:34

SAN DIEGO AND VANCOUVER, Aug. 5, 2013 /PRNewswire/ - Sophiris Bio Inc. (Sophiris, TSX: SHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced financial results and recent key operational highlights for the three and six months ended June 30, 2013. Recent Key Operational Highlights -- On July 15, 2013, the Company...

2013-07-15 08:26:50

SAN DIEGO, CA and VANCOUVER, July 15, 2013 /PRNewswire/ - Sophiris Bio Inc. (Sophiris, TSX: SHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced the appointment of Joseph Turner to its Board of Directors effective and contingent upon the closing of the Company's proposed initial U.S. public offering of its common shares and listing...

2013-07-12 16:22:05

SAN DIEGO & VANCOUVER, July 12, 2013 /PRNewswire/ - Sophiris Bio Inc. (Sophiris, TSX: SHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing a clinical-stage, targeted treatment for benign prostatic hyperplasia (BPH or enlarged prostate), today announced the resignation of both Noah Knauf and Amit Sobti, the Warburg Pincus nominees to its Board of Directors. The resignation of the Warburg Pincus nominees is in conjunction with the independent sales...

2013-04-30 16:30:20

SAN DIEGO, CA and VANCOUVER, April 30, 2013 /PRNewswire/ - Sophiris Bio Inc. (Sophiris, TSX: SHS) (the "Company" or "Sophiris"), a urology company developing a clinical-stage, targeted treatment for benign prostatic hyperplasia (BPH or enlarged prostate), today announced financial results and recent key operational highlights for the first quarter ended March 31, 2013. Recent Key Operational Highlights -- Based on feedback from a guidance meeting with the U.S. Food...

2013-02-18 16:21:45

This release has been updated to correct the expected start date of the first pivotal trial for PRX302 to "in the first half of 2013." SAND DIEGO and VANCOUVER, Feb. 18, 2013 /PRNewswire/ - Sophiris Bio Inc. (Sophiris, TSX: SHS) ("Sophiris" or the "Company"), a biopharmaceutical company developing a treatment for benign prostatic hyperplasia (BPH or enlarged prostate), previously announced on February 15, 2013 that it has filed a registration statement on Form S-1 with the U.S....

2013-02-15 20:21:07

SAN DIEGO, CA and VANCOUVER, BC, Feb. 15, 2013 /PRNewswire/ - Sophiris Bio Inc. (Sophiris, TSX: SHS) ("Sophiris" or the "Company"), a biopharmaceutical company developing a treatment for benign prostatic hyperplasia (BPH or enlarged prostate), announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial U.S. public offering of its common shares on the NASDAQ stock market. The Company has...